EGFR antibody

• Catalog Number: orb348869
• Category: Antibodies
• Description: Human monoclonal antibody to EGFR
• Species/Host: Human
• Clonality: Monoclonal
• Clone Number: Matuzumab
• Tested applications: Blocking, ELISA, FC, IF, WB
• Reactivity: Human
• Isotype: IgG1
• Immunogen: The parental mouse antibody was generated by immunizing BALB/c mice intraperitoneally with A431 cells in phosphate buffered saline (PBS). Later on the humanzied version of the antibody was created by grafting CDRs of the murine antibody onto human constant regions.
• Concentration: 1 mg/ml
• Purity: Purified
• Conjugation: Unconjugated
• Target: EGFR
• UniProt ID: P00533
• Storage: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
• Buffer/Preservatives: PBS with 0.02% Proclin 300.
• Alternative names: ErbB-1; ERBB1; HER1; EGF; Epidermal growth factor
• Note: For research use only
• Application notes: This antibody is derived from a mouse parental clone mAb 425 which has demonstrated anti-tumor activity against solid tumors in phase I clinical trials. The binding characterization of this antibody to human EGFR was done using ELISA. This antibody was also found to bind human EGFR with a similar avidity as the parental mouse antibody 425 (PMID: 1798701). The parental mouse antibody 425 in combination with C225 (Cetuximab) reduced growth and survival of EGFR overexpressing MDA-MB-468 breast cancer cells more effectively than either antibody alone. The combination was also reported to effectively inhibited AKT and MAPK phosphorylation in MDA-MB-468 cell (PMID: 18424917). This antibody was used in a phase 1 study to investigate the safety and tolerability and to explore the pharmacokinetic and pharmacodynamic profile in patients with solid tumors that express EGFR (PMID: 14701780). This antibody has been used in various phase I studies alone or in combination with other therapeutic agents to treat patients with various type of cancers (PMID: 16533873; 16622465; 19238629). A study reported that the antitumor effects of matuzumab and cetuximab depend on inhibition of EGFR downstream signaling mediated by Akt or Erk rather than on inhibition of EGFR itself (PMID: 18033688).
• Expiration Date: 12 months from date of receipt.

References

Murthy, U. et al. Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide Arch Biochem Biophys, 252, 549-560 (1987)

PubMed: 2434025

Reactivity

Human

Immunofluorescence analysis of rat stomach tissue using EGFR antibody (dilution of primary antibody - 5 ug/ml)

IHC-P image of mouse ovary tissue using EGFR antibody (dilution of primary antibody at 5 ug/ml)

IHC-P image of rat stomach tissue using EGFR antibody (dilution of primary antibody at 5 ug/ml)

IHC-P image of rat stomach tissue using EGFR antibody (dilution of primary antibody at 5 ug/ml)

Immunohistochemical staining of mouse skin tissue using anti-EGFR (dilution of primary antibody - 5 ug/ml)

IHC-P staining of human breast cancer tissue using anti-EGFR (dilution at 5 ug/ml)

Immunohistochemical staining of paraffin embedded rat lung tissue using anti-EGFR (primary antibody at 5 ug/ml)

Western blot analysis of human lung cancer (lane 1), human breast cancer (lane 2), rat skin (lane 3), U251 cells (lane 4); Hela cells (lane 5) using EGFR antibody (2.5 ug/ml)